A hedonic model of pricing of innovative pharmaceuticals

Health Policy and High-Tech Industrial Development: Learning from Innovation in the Health Industry

Volumn , Issue , 2005, Pages 77-100

  Comanor, William S ^a   Schweitzer, Stuart O ^a   Carter, Tanja ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PEPPERDINE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548354108     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4337/9781845424565.00014     Document Type: Chapter

References (26)

1. Abramowicz, M. (ed.), The Medical Letter, 38, 16 February 1996, 39, 11 April 1997, New Rochelle, NY.
2. Berkow, R. (ed.), The Merck Manual, 16th edn, MerckResearch Laboratories, 1992.
3. Berndt, Ernst R., Iain M. Cockburn and Avi Griliches, ‘Pharmaceutical innovations and market dynamics, tracking effects on price indexes for antidepressant drugs’, Brookings Papers: Microeconomics, 1996, 133-88.
4. Cockburn, Iain M. and Aslam H. Anis, ‘Hedonic analysis of arthritis drugs’, working paper 6574, National Bureau of Economic Research, May 1998.
5. Comanor, W.S., ‘The political economy of the pharmaceutical industry’, Journal of Economic Literature, 24, September 1986, 1178-217.
6. Comanor, W.S., ‘The pharmaceutical research and development process and its costs’, Drugs for Communicable Diseases: Stimulating Development and Securing Availability, Médecins Sans Frontières, Paris, 1999.
7. Comanor, W.S. and S.O. Schweitzer, ‘Pharmaceuticals’, in Walter Adams and James Brock (eds), The Structure of American Industry, 9th edn, 1995, pp.177-96.
8. Congressional Budget Office, ‘How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry’, July 1998, available at www.cbo.gov.
9. Cowling, K. and J. Cubbin, ‘Price, quality and advertising competition: an econometric investigation of the United Kingdom car market’, Economica, 38, November 1971, 378-94.
10. Dimasi, J., R.W. Hansen, H.G. Giabowski and L. Lasagna, ‘The cost of innovation in the pharmaceutical Industry’, Journal of Health Economics, 10, 1991, 107-42.
11. Ellison, Sara Fisher and Judith K. Hellerstein, ‘The economics of antibiotics: an exploratory study’, in Jack E. Triplett (ed.), Measuring the Prices of Medical Treatments, Washington: Brookings Press, 1999, pp.118-43.
12. Epple, Dennis, ‘Hedonic prices and implicit markets: estimating demand and supply functions for differentiated products’, Journal of Political Economy, February 1987, 95, 59-80.
13. Feenstra, Robert C., ‘Exact hedonic price indexes’, Review of Economics and Statistics, 77, November 1995, 634-53.
14. Frank, R. and David Salkever, ‘Generic entry and the pricing of pharmaceuticals’, Journal of Economics and Management Strategy, 6, 1997, 75-90.
15. Griliches, Z., ‘Hedonic price indexes for automobiles: an econometric analysis of quality change’, The Price Statistics of the Federal Government (general series no. 73), New York: National Bureau of Economic Research, 1961, pp.137-96.
16. Griliches, Z., ‘Introduction: hedonic price indexes revisited’, Price Indexes and Quality Change: Studies in New Methods and Measurement, Cambridge: Harvard University Press, 1971, pp.3-15.
17. Kettler, Hannah E., Updating the Cost of a New Chemical Entity, London: Office of Health Economics, 1999.
18. Kmenta, Jan, Elements of Econometrics, London: Macmillan, 1986.
19. Lacy, Charles et al., Drug Information Handbook, 6th edn, Hudson, OH: Lexi-Comp, Inc., 1998-99.
20. Lancaster, K.J., Consumer Demand: A New Approach, New York: Columbia University Press, 1971.
21. Lu, Z. John and William S. Comanor, ‘Strategic pricing of new pharmaceuticals’, Review of Economics and Statistics, February 1998, 108-18.
22. Reiffen, David and Michael R.Ward, ‘Generic Drug Industry Dynamics’, working paper, US Treasury Department, October 2002.
23. Suslow, Valarie Y., ‘Measuring quality change in the market for anti-ulcer drugs’, in Robert B. Helms (ed.), Competitive Strategies in the Pharmaceutical Industry, Washington: American Enterprise Institute, 1996.
24. Teitelbaum, Fred, ‘Drug Trend Report 2002', Express Scripts, Inc., June 2003.
25. Triplett, J.E., ‘Automobiles and hedonic quality measurement’, Journal of Political Economy, 77, 1969, 408-17.
26. US Congress, Office of Technology Assessment, ‘Pharmaceutical Research & Development: Costs, Risks, and Reward’, February 1993, pp.50-72.